Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has successfully expanded its Cortrophin sales force, a significant factor contributing to the product’s success, providing the company with increased financial flexibility for future investment in this area. Evidence from the weekly TRx tracker indicates that Cortrophin is likely to outperform previous revenue expectations, leading to enhanced revenue estimates and potential multiple expansion. Additionally, ANI's data-driven approach enhances its capability to address payer-related inquiries and secure approval for patient prescriptions, further strengthening its market position.

Bears say

ANI Pharmaceuticals Inc. faces significant challenges that contribute to a negative outlook regarding its stock, chiefly characterized by a substantial debt load exceeding $600 million, which may strain financial stability and operational flexibility. Additionally, the company encounters multiple risks, including pricing pressures across its portfolio of branded and generic drugs, reimbursement uncertainties, and competitive threats, all of which could adversely impact revenue generation. Furthermore, past reputational issues in the ACTH market have raised concerns about commercial execution and could hinder the company’s ability to navigate the complexities of the pharmaceutical landscape effectively.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.